These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20505985)

  • 1. Nanoparticles: a promising modality in the treatment of sarcomas.
    Susa M; Milane L; Amiji MM; Hornicek FJ; Duan Z
    Pharm Res; 2011 Feb; 28(2):260-72. PubMed ID: 20505985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies in melanoma therapy: can nanoparticles overcome chemoresistance?
    Badea I
    Nanomedicine (Lond); 2017 Jul; 12(14):1623-1626. PubMed ID: 28635551
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in nanomedicine for enhanced cancer chemotherapy.
    Wei G; Wang Y; Yang G; Wang Y; Ju R
    Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine to overcome cancer multidrug resistance.
    Yang X; Yi C; Luo N; Gong C
    Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular-targeted nanotherapies in cancer: enabling treatment specificity.
    Blanco E; Hsiao A; Ruiz-Esparza GU; Landry MG; Meric-Bernstam F; Ferrari M
    Mol Oncol; 2011 Dec; 5(6):492-503. PubMed ID: 22071376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine: An effective tool in cancer therapy.
    Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
    Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine: the promise and challenges in cancer chemotherapy.
    Naguib YW; Cui Z
    Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
    [No Abstract]   [Full Text] [Related]  

  • 16. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles.
    Zhang BF; Xing L; Qiao JB; Cui PF; Wang FZ; Zhang JL; Xu CX; Jiang HL
    Int J Pharm; 2016 Jun; 506(1-2):207-13. PubMed ID: 27113867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
    Du M; Ouyang Y; Meng F; Ma Q; Liu H; Zhuang Y; Pang M; Cai T; Cai Y
    Nanomedicine (Lond); 2019 Jul; 14(13):1771-1786. PubMed ID: 31298065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.